심방세동 환자에서 새로 개발된 R2CHA2DS2-VASc score 유용성 및 CHADS2, CHA2DS2-VASc scores와의 비교연구 = The usefulness of newly developed R2CHA2DS2-VASc score and comparison with CHADS2 and CHA2DS2-VASc scores in atrial fibrillation patients

다국어 초록 (Multilingual Abstract)

Background: The decision to administer oral anticoagulation therapy depends on accurate assessment of stroke risk in patients with atrial fibrillation (AF). Various stroke risk stratification schemes have been developed to help inform clinical decision making. The CHADS2 and CHA2DS2-VASc scores have been used in estimating the risk of stroke in patients with AF. Recently R2CHA2DS2-VASc score was developed. The objective of the current study is to validate the usefulness of the R2CHA2DS2-VASc score and to compare the accuracy of the CHADS2, CHA2DS2-VASc, and R2CHA2DS2-VASc scores in predicting a patient’s risk of stroke. Methods: Based on medical records, we conducted a retrospective study of patients hospitalized with AF from March 2011 to July 2013. A total of 448 AF patients were included in this study. The receiver operating characteristic (ROC) curve analysis in MedCalc was used for comparison with respective diagnostic values. Results: The patient characteristics showed male predominance (60.9%). Among the 448 AF patients, 131 (29.2%) patients had strokes during the study. A R2CHA2DS2-VASc score of more than 5 is the optimal cut-off value for prediction of stroke. A risk score of three, the area under the ROC curve (AUC) of R2CHA2DS2- VASc score (AUC 0.631; 95% confidence interval, 0.585-0.679) was the highest. A significant difference was observed between AUC for R2CHA2DS2-VASc, CHADS2, and CHA2DS2-VASc scores, but no meaningful difference between CHADS2 and CHA2DS2-VASc scores. Conclusion: We determined the usefulness of the R2CHA2DS2-VASc score, which showed better association with stroke than the CHADS2 and CHA2DS2-VASc scores.

참고문헌 (Reference)

1 Lip GY., "The CHA2DS2-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief history" 36 : 2880-2885, 2015

2 Gage BF, "Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin" 110 : 2287-2292, 2004

3 Wolf PA, "Secular trends in the prevalence of atrial fibrillation:The Framingham Study" 131 : 790-795, 1996

4 Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation" 361 : 1139-1151, 2009

5 Kornej J, "Comparing the ‘new’ R2CHADS2 with the ‘old’ CHA2DS2-VASc scores for predicting thromboembolism in patients undergoing atrial fibrillation ablation: new does not mean better" 30 : 385-387, 2014

6 O'Brien EC, "Comparative performance of the R2Chads2, Chads2, and Cha2Ds2-vasc scores in atrial fibrillation" 132 (132): A17202-, 2015

7 Gage BF, "Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)" 151 : 713-719, 2006

8 Kiliszek M, "CHA2DS2-VASc and R2CHA2DS2-VASc scores have predictive value in patients with acute coronary syndromes" 125 : 545-552, 2015

9 Wolf PA, "Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study" 147 : 1561-1564, 1987

10 Miller PS, "Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?" 36 : 360-366, 2005

11 Bautista J, "Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure" 8 : 226-231, 2015

12 Jang IM, "A rate of anticoagulation for the prevention of ischemic stroke in the patients with atrial fibrillation" 14 : 285-289, 2008